Analysts Set Aurinia Pharmaceuticals Inc (AUPH) PT at $11.48

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has been assigned a consensus rating of “Buy” from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $11.48.

Several equities research analysts have recently weighed in on the company. BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 24th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 20th. Seaport Global Securities restated a “buy” rating and issued a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, March 16th. Cantor Fitzgerald set a $16.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock an “overweight” rating in a research report on Thursday, March 15th. Finally, Royal Bank of Canada began coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, February 8th. They issued an “outperform” rating and a $9.00 price objective on the stock.

How to Become a New Pot Stock Millionaire

Several hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in shares of Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Cutler Capital Management LLC grew its position in Aurinia Pharmaceuticals by 25.0% during the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 10,000 shares during the last quarter. Alyeska Investment Group L.P. grew its position in Aurinia Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after acquiring an additional 12,171 shares during the last quarter. Kazazian Asset Management LLC grew its position in Aurinia Pharmaceuticals by 11.6% during the fourth quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock valued at $707,000 after acquiring an additional 16,189 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 26,395 shares during the last quarter. Institutional investors own 28.50% of the company’s stock.

Shares of NASDAQ:AUPH remained flat at $$5.19 during midday trading on Wednesday. The stock had a trading volume of 306,120 shares, compared to its average volume of 715,285. Aurinia Pharmaceuticals has a 12-month low of $4.41 and a 12-month high of $8.19. The company has a market capitalization of $436.23, a PE ratio of -5.64 and a beta of 2.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.10. Aurinia Pharmaceuticals had a negative return on equity of 17.54% and a negative net margin of 16,855.24%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the prior year, the business posted ($0.11) earnings per share. The company’s revenue was up .0% on a year-over-year basis. sell-side analysts expect that Aurinia Pharmaceuticals will post -0.7 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Analysts Set Aurinia Pharmaceuticals Inc (AUPH) PT at $11.48” was reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/03/31/analysts-set-aurinia-pharmaceuticals-inc-auph-pt-at-11-48.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply